Replies to post #212200 on Biotech Values

[DewDiligence]

RARX -30% on additional phase-2 data in PNH:

https://www.businesswire.com/news/home/20171204005307/en

The stock sold off sharply in June following the release of initial data from the same trial (#msg-132539440).